| 영문 | radiation therapy | 한글 | 방사선요법 |
|---|---|---|---|
| 설명 | X선, γ선의 전자방사선이나 전자선, 양자선, 중성자선 등의 입자방사선을 이용해, 주로 악성 종양 치료를 목적으로 하는 치료법이다. 암세포가 주위의 정상세포보다도 방사선 감수성이 높은 점을 이용하여, 정상세포의 손상을 가능한 한 최소로 억제하면서 암세포를 파괴한다. 사용되는 방사선에는 밀봉소선원에서 나오는 γ선, 직선가속기에서 얻어지는 고에너지 X선과 전자선, 텔레코발트장치에 의한 60Co의 γ선과, 베타트론에 의한 전자선, 사이크로트론에서 얻어지는 양자선, 중성자선 등이 있다. |
||
| 영문 | radiation therapy | 한글 | 방사선치료 |
|---|---|---|---|
| 설명 | 방사선의 살균효과나 세포를 죽이는 효과를 치료에 이용하는 방법으로, 좁은 의미로 암의 방사선치료를 의미한다. 암에 대한 방사선치료는 암세포를 죽이는데 효과가 큰 베타선을 주로 사용한다. 하지만, 이런 방사선치료는 정상세포에도 큰 영향을 끼쳐 이에 따른 기능의 장애를 가져올 수 있다. 따라서 방사선치료에 있어서는 단지 그 암세포에 대한 작용뿐만 아니라, 정상세포에 대한 작용도 고려하여 시행한다. |
||
| 영문 | speech therapy | 한글 | 언어치료 |
|---|---|---|---|
| 설명 | 말을 정확하게 발음할 수 없거나 더듬는 환자에게 발음, 대화 따위의 훈련을 전문적으로 행하는 치료법. |
||
| 영문 | therapy | 한글 | 요법 |
|---|---|---|---|
| 설명 | 병을 낫게 하는 것 또는 그 방법. |
||
| 영문 | gene therapy | 한글 | 유전자요법 |
|---|---|---|---|
| 설명 | 유전병을 치료할 목적으로, 정상적으로 기능하는 단일유전자 혹은 복수유전자를 어떤 기원에서 얻어내어 생세포에 도입하는 것. 유전물질은 유전자삽입 조작에 의해 수용세포에로 도입된다. 즉, 유전자를 끼워 넣은 새로운 세포를 사용하는 치료로서 1980년 미국의 학자가 지중해빈혈환자에게 강행하여 비판을 받았지만, 미국 국립보건연구소는 1990년 9월 아데노신 데아미나아제(adenosine deaminase, ADA) 결핍증 환자의 림프구에 ADA 유전자를 끼워 넣는 치료를 시작한 이래 현재는 암을 포함한 많은 질병들을 치료하는 목적으로 쓰인다. |
||
| HIV encephalopathy | <immunology> A frequent cerebral condition in people with AIDS that results in the loss of cognitive capacity, affecting the ability to function in a social or occupational setting. Its cause has not been determined exactly, but may result from HIV infection of cells in the brain or an inflammatory reaction to such infection. (09 Oct 1997) |
|---|---|
| HIV enhancer | Cis-acting regulatory sequences in the HIV long terminal repeat (ltr) which play a major role in induction or augmentation of HIV gene expression in response to environmental stimuli such as mitogens, phorbol esters, or other viruses. The HIV enhancer is the binding site for many cellular transcription factors including the nuclear factor nf-kappa b. (12 Dec 1998) |
| HIV enteropathy | Chronic, well-established diarrhoea (greater than one month in duration) without an identified infectious cause after thorough evaluation, in an HIV-positive individual. It is thought to be due to direct or indirect effects of HIV on the enteric mucosa. HIV enteropathy is a diagnosis of exclusion and can be made only after other forms of diarrhoeal illness have been ruled out. (12 Dec 1998) |
| HIV envelope protein gp120 | External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120,000 kD and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably t4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV. (12 Dec 1998) |
| HIV envelope protein gp160 | An envelope protein of the human immunodeficiency virus that is encoded by the HIV env gene. It has a molecular weight of 160,000 kD and contains numerous glycosylation sites. It serves as a precursor for both the HIV envelope protein gp120 and the HIV envelope protein gp41. (12 Dec 1998) |
| HIV envelope protein gp41 | Transmembrane envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The n-terminal part of gp41 is thought to be involved in cell fusion with the CD4 antigens of t4 lymphocytes, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by immunoblotting. (12 Dec 1998) |
| HIV infections | Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru aids-related complex (arc), to acquired immunodeficiency syndrome (aids). (12 Dec 1998) |
| HIV integrase | <enzyme> Enzyme of the human immunodeficiency virus that is required to integrate viral DNA into cellular DNA in the nucleus of a host cell. HIV integrase is a DNA nucleotidyltransferase encoded by the pol gene. Registry number: EC 2.7.7.- (12 Dec 1998) |
| HIV integrase inhibitors | Inhibitors of HIV integrase, an enzyme required for integration of viral DNA into cellular DNA. (12 Dec 1998) |
| HIV long-terminal repeat | Regulatory sequences important for viral replication that are located on each end of the HIV genome. The ltr includes the HIV enhancer, promoter, and other sequences. Specific regions in the ltr include the negative regulatory element (nre), nf-kappa b binding sites , sp1 binding sites, tata box, and trans-acting responsive element (tar). The binding of both cellular and viral proteins to these regions regulates HIV transcription. (12 Dec 1998) |
| HIV protease | <enzyme> Enzyme of the human immunodeficiency virus that is required for post-translational cleavage of gag and gag-pol precursor polyproteins into functional products needed for viral assembly. HIV protease is an aspartic protease encoded by the amino terminus of the pol gene. Registry number: EC 3.4.23.- (12 Dec 1998) |
| HIV protease inhibitors | Inhibitors of HIV protease, an enzyme required for production of proteins needed for viral assembly. (12 Dec 1998) |
| HIV seronegativity | Immune status consisting of non-production of HIV antibodies, as determined by various serological tests. (12 Dec 1998) |
| HIV seropositivity | Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/lav). (12 Dec 1998) |
| HIV seroprevalence | Studies of the number of cases where human immunodeficiency virus (HIV) is present in a specific population at a designated time. The presence in a given individual is determined by the finding of HIV antibodies in the serum (HIV seropositivity). (12 Dec 1998) |